Chemoradiation or Brachytherapy for Rectal Cancer

Completed · Phase 2

Conditions studied: Rectal Cancer

In brief

This research is being done to compare the effectiveness of high dose endorectal brachytherapy (END-HDR) and the standard treatment option of chemoradiation with Capecitabine in the treatment of cancer of the lowest part of the bowel (rectum).

Key facts

Study ID

NCT02017704

Run by

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

People needed

9

Starts

2014-06-12

Expected to finish

2023-01-31

Last updated by the study team

2023-10-17

Who can join

Age: 18 and older, up to 100. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Confirmed adenocarcinoma of the rectum
• Appropriate tumor staging and location
• Patients should be suitable candidates for surgery and chemotherapy
• ECOG/WHO performance status 0-1
• Patients must be 18 years or older
• No previous history of pelvic radiation
• Patients must have acceptable organ and marrow function
• Non pregnant, non-breast feeding females under active contraception
• Ability to understand and willingness to sign a written informed consent document.

You may not qualify if…

• Evidence of distant metastatic disease
• Evidence of sphincter invasion on MRI
• Prior history of radiation to the pelvis
• Prior malignancy except for adequately treated basal cell or squamous cell skin cancer, cervical carcinoma in situ, DCIS, or other cancer from which the patient has been disease free for at least 3 years
• Presence of multiple small bowel loops trapped within the immediate tumor bed (post hysterectomy or prostatectomy).
• Use of any investigational agent within the 4 weeks preceding enrollment
• Previous exposure to chemotherapy for rectal cancer
• Uncontrolled intercurrent illness including but not limited to, ongoing or active infections (or infections requiring systemic treatment), symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
• Pregnant and breastfeeding women are excluded, as well as women of child-bearing potential who are unwilling or unable to use an acceptable method of birth control (hormonal or barrier method of birth control; abstinence) to avoid pregnancy for the duration of the study. Should a woman become pregnant or suspect she is pregnant while participating in this study she should inform her treating physician immediately.
• Women who are not post-menopausal and have a positive urine or serum pregnancy test or refuse to take a pregnancy test.
• Contraindication for safe MRI, implants, or other conditions that interfere with imaging required for the study (e.g., pacemaker or non-MRI compatible hip prostheses). Note: Subjects with bilateral hip implants are not eligible for the study. Subjects with a unilateral hip implant may be eligible assuming the implant is MRI compatible and does not present artifact on MRI in the areas of interest.
• Subject is pacemaker dependent.

Where it is running

• Moffitt Cancer Center — Tampa, Florida, United States
• Winship Cancer Institute, Emory University — Atlanta, Georgia, United States
• The SKCCC at Johns Hopkins — Baltimore, Maryland, United States
• Beth Israel Hospital — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.